全文获取类型
收费全文 | 19535篇 |
免费 | 2017篇 |
国内免费 | 448篇 |
专业分类
耳鼻咽喉 | 151篇 |
儿科学 | 369篇 |
妇产科学 | 448篇 |
基础医学 | 1656篇 |
口腔科学 | 816篇 |
临床医学 | 2630篇 |
内科学 | 2334篇 |
皮肤病学 | 381篇 |
神经病学 | 2887篇 |
特种医学 | 455篇 |
外国民族医学 | 3篇 |
外科学 | 1847篇 |
综合类 | 1915篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 1648篇 |
眼科学 | 279篇 |
药学 | 2072篇 |
25篇 | |
中国医学 | 1481篇 |
肿瘤学 | 601篇 |
出版年
2024年 | 26篇 |
2023年 | 520篇 |
2022年 | 553篇 |
2021年 | 1109篇 |
2020年 | 1002篇 |
2019年 | 988篇 |
2018年 | 928篇 |
2017年 | 886篇 |
2016年 | 747篇 |
2015年 | 835篇 |
2014年 | 1563篇 |
2013年 | 1851篇 |
2012年 | 1191篇 |
2011年 | 1165篇 |
2010年 | 951篇 |
2009年 | 873篇 |
2008年 | 835篇 |
2007年 | 846篇 |
2006年 | 802篇 |
2005年 | 682篇 |
2004年 | 562篇 |
2003年 | 438篇 |
2002年 | 385篇 |
2001年 | 283篇 |
2000年 | 240篇 |
1999年 | 219篇 |
1998年 | 153篇 |
1997年 | 122篇 |
1996年 | 118篇 |
1995年 | 95篇 |
1994年 | 98篇 |
1993年 | 64篇 |
1992年 | 86篇 |
1991年 | 80篇 |
1990年 | 67篇 |
1989年 | 76篇 |
1988年 | 58篇 |
1987年 | 35篇 |
1986年 | 53篇 |
1985年 | 75篇 |
1984年 | 60篇 |
1983年 | 53篇 |
1982年 | 43篇 |
1981年 | 43篇 |
1980年 | 38篇 |
1979年 | 27篇 |
1978年 | 18篇 |
1977年 | 16篇 |
1976年 | 11篇 |
1975年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 23 毫秒
1.
《Research in social & administrative pharmacy》2022,18(9):3492-3500
BackgroundPolypharmacy is commonly related to poor drug adherence, decreased quality of life and inappropriate prescribing in eldery. Furthermore, this condition also leads to a higher utilization of health services resources, due to the increased risk of adverse drug events, length of stays in hospitals and readmissions rates after discharge.ObjectiveThis Systematic Review aimed to synthesize the current evidence that evaluates pharmaceutical services on polymedicated patients, from an economic perspective.MethodsSystematic searches were conducted in MEDLINE, SCOPUS and Cochrane Library databases to identify studies that were published until January 2021. Experimental and observational studies were included in this review, using strict inclusion/exclusion criteria and were assessed for quality using the following tools: RoB and ROBINS-I. Two independent reviewers selected the articles and extracted the data.Results3,662 articles were retrieved from the databases. After the screening, 18 studies were included: 9 experimental and 9 observational studies. The studies reported that the integration of the pharmacist as a member of the healthcare team provides an optimized use of pharmacotherapy to polymedicated patients and contributes to health promotion, providing reduction of spending on medication, reduction of expenses related to emergency care and hospitalizations and other medical expenses. The ECRs made cost-effectiveness or cost-benefit analysis, and most of the Non Randomized studies had statistically significant cost savings even considering the expenses of pharmaceutical assistance. Experimental studies reported a cost reduction varying between US$ 193 to US$ 4,966 per patient per year. Furthermore, observational studies estimated a cost reduction of varying from US$ 3 to US$ 2,505 per patient per year. The cost savings are related to decrease in emergency visits and hospitalizations, through pharmacist intervention (medication review and pharmacotherapy follow-up).ConclusionsConsidering the set of studies included, pharmaceutical care services directed to polymedicated patients may cooperate to save financial resources. Most of the interventions showed positive economic trends and also contributed to improving clinical parameters and quality of life. However, due to the majority of the studies having exploratory or qualitative methodology, it is essential to carry out more robust studies, based on full economic evaluation. 相似文献
2.
《Research in social & administrative pharmacy》2022,18(3):2367-2391
ObjectivesSeveral implementation strategies can reduce potentially inappropriate medication (PIM) prescribing. Although use of PIMs has declined in recent years, it remains prevalent. Various strategies exist to improve the appropriateness of medication use. However, little is known about the processes of these different implementation strategies. This scoping review aims to investigate how the process evaluation of implementation strategies for reducing PIM prescribing in the older population has been studied.MethodsWe searched for process evaluations of implementation strategies for reducing PIM prescribing in PUBMED, SCOPUS and Web of Science published between January 2000 and November 2019 in English. We applied the following inclusion criteria: patients aged ≥65 years, validated PIM criteria, and implementation process evaluated. The review focuses on decision support for health care professionals. We described the findings of the process evaluations, and compared the authors’ concepts of process evaluation of the included publications to those of Proctor et al.( 2010).ResultOf 9131 publications screened, 29 met our inclusion criteria. Different process evaluation conceptualizations were identified. Most process evaluations took place in the initial stages of the process (acceptability, adoption, appropriateness, and feasibility) and sustainability and implementation costs were seldom evaluated. None of the included publications evaluated fidelity.Multifaceted interventions were the most studied implementation strategies. Medication review was more common in acceptability evaluations, multidisciplinary interventions in adoption evaluations, and computerized systems and educational interventions in feasibility evaluations. Process evaluations were studied from the health care professionals’ viewpoint in most of the included publications, but the management viewpoint was missing.DiscussionThe conceptualization of process evaluation in the field of PIM prescribing is indeterminate. There is also a current gap in the knowledge of sustainability and implementation costs. Clarifying the conceptualization of implementation process evaluation is essential in order to effectively translate research knowledge into practice. 相似文献
3.
Efficacy of Curcumin in Combination with Intralesional Dexamethasone with Hyaluronidase in the Treatment of Oral Submucous Fibrosis: A Randomized Controlled Trial 下载免费PDF全文
Sagar AdhikariJyotsna RimalIccha Kumar MaharjanAshish Shrestha 《Asian Pacific journal of cancer prevention》2022,23(9):3125-3132
Objective: The objective of this study was to determine the efficacy of curcumin in combination with intralesional dexamethasone with hyaluronidase in the treatment of oral submucous fibrosis (OSF). Methods: This randomized, double blind, parallel design, clinical trial was conducted at B.P. Koirala Institute of Health Sciences, Nepal. Thirty-four patients with clinically diagnosed OSF were randomized into two groups (17 participants in each) with baseline treatment of intralesional dexamethasone with hyaluronidase for 6 weeks for the both. Curcumin (2gm/day) was provided to Group A (Test) and Group B (Control) received placebo. Interincisal mouth opening, tongue protrusion, cheek flexibility and visual analogue scale (VAS) scoring of burning sensation of oral mucosa was recorded at baseline, 6, 8 and 12 weeks follow-up and independent t-test was used to compare the improvements in two groups. Results: On comparing the 6 weeks and baseline values, in Group A and B the mean difference in mouth opening was 8.82±1.33 mm and 5.53±1.17 mm respectively (p<0.001), in cheek flexibility was 2.94±1.02 mm and 1.94±1.24 mm respectively (p=0.02) and in tongue protrusion was 6.23±1.48 and 3.65±1.37 mm respectively (p<0.001). The findings were consistent in the 8 weeks follow-up. In 12 weeks follow-up, on comparing with the baseline values, in Group A and B, the mean difference in mouth opening was 8.71±1.16 mm and 5.35±1.22 mm respectively (<0.001), ), in cheek flexibility was 2.81±1.01 mm and 1.76±1.35 mm respectively (p=0.02) and in tongue protrusion was 6.06±1.48 and 3.35±1.50 mm respectively (p<0.001). Both the arms showed 100% improvement in burning sensation in 6, 8 and 12 weeks follow-up. Conclusion: Curcumin in combination with intralesional dexamethasone with hyaluronidase is efficacious in the treatment of OSF. 相似文献
4.
Idris Olasunmbo Ola Kirsi Talala Teuvo Tammela Kimmo Taari Teemu Murtola Paula Kujala Jani Raitanen Anssi Auvinen 《International journal of cancer. Journal international du cancer》2023,152(4):672-678
Prostate-specific antigen (PSA)-based screening for prostate cancer (PCa) can reduce PCa mortality, but also involves overdetection of low-risk disease with potential adverse effects. We evaluated PCa incidence among men with PSA below 3 ng/mL and no PCa diagnosis at the first screening round of the Finnish Randomized Study of Screening for PCa. Follow-up started at the first screening attendance and ended at PCa diagnosis, emigration, death or the common closing date (December 2016), whichever came first. Cox regression analysis was used to estimate hazard ratios and their confidence intervals (CI). Among men with PSA <3 ng/mL, cumulative PCa incidence was 9.1% after 17.6 years median follow-up. Cumulative incidence was 3.6% among men with baseline PSA 0 to 0.99 ng/mL, 11.5% in those with PSA 1.0 to 1.99 ng/mL and 25.7% among men with PSA 2 to 2.99 ng/mL (hazard ratio 9.0, 95% CI: 7.9-10.2 for the latter). The differences by PSA level were most striking for low-risk disease based on Gleason score and EAU risk group. PSA values <1 ng/mL indicate a very low 20-year risk, while at PSA 2 to 2.99 ng/mL risks are materially higher, with 4- to 5-fold risk for aggressive disease. Using risk-stratification and appropriate rescreening intervals will reduce screening intensity and overdetection. Using cumulative incidence of clinically significant PCa (csPCa) as the criterion, rescreening intervals could range from approximately 3 years for men with initial PSA 2 to 2.99 ng/mL, 6 years for men with PSA 1 to 1.99 ng/mL to 10 years for men with PSA <1 ng/mL. 相似文献
5.
目的 观察张氏头针治疗儿童多发性抽动症的临床疗效。方法 2019年3月至2020年12月共招募多发性抽动症儿童60例,随机分为头针组和硫必利组,每组各30例。头针组采用毫针针刺双侧运动区、舞蹈震颤控制区及百会、印堂,每周治疗3次,1个月为1个疗程,共治疗4个疗程;硫必利组给予盐酸硫必利片50-100 mg/次,2次/天,1个月为1个疗程,共治疗4个疗程。比较两组患者治疗前后耶鲁综合抽动严重程度量表(Yale global Tic severity scale,YGTSS)、中医证候积分、SF-36健康调查简表(the MOS item short from health survey,SF-36)及临床疗效评价结果。结果 头针组合硫必利组组内比较:二组的YGTSS评分、中医证候积分与治疗前相比具有显著统计学差异(P<0.05),SF-36评分中头针组在生理功能、生理职能、总体健康、情感职能、心理健康等5个维度的评分高于治疗前,差异有统计学意义(P<0.05);硫必利组在生理功能、生理职能、总体健康、心理健康等5个维度的评分高于治疗前,差异有统计学意义(P<0.05);头针组合硫必利组组间比较:头针组治疗后YGTSS评分、中医证候积分均低于硫必利组,差异有统计学意义(P<0.05),头针组在SF-36量表中总体健康和心理健康2个维度照优于硫必利组,差异有统计学意义(P<0.05);治疗结束3个月随访,头针组YGTSS评分、中医证候积分均低于硫必利组,差异有统计学意义(P<0.05)。结论 张氏头针能够很好的改善多发性抽动症的临床症状,提高其生活质量。 相似文献
6.
7.
8.
9.
《Value in health》2022,25(3):340-349
ObjectivesThis study aimed to systematically review recent health economic evaluations (HEEs) of artificial intelligence (AI) applications in healthcare. The aim was to discuss pertinent methods, reporting quality and challenges for future implementation of AI in healthcare, and additionally advise future HEEs.MethodsA systematic literature review was conducted in 2 databases (PubMed and Scopus) for articles published in the last 5 years. Two reviewers performed independent screening, full-text inclusion, data extraction, and appraisal. The Consolidated Health Economic Evaluation Reporting Standards and Philips checklist were used for the quality assessment of included studies.ResultsA total of 884 unique studies were identified; 20 were included for full-text review, covering a wide range of medical specialties and care pathway phases. The most commonly evaluated type of AI was automated medical image analysis models (n = 9, 45%). The prevailing health economic analysis was cost minimization (n = 8, 40%) with the costs saved per case as preferred outcome measure. A total of 9 studies (45%) reported model-based HEEs, 4 of which applied a time horizon >1 year. The evidence supporting the chosen analytical methods, assessment of uncertainty, and model structures was underreported. The reporting quality of the articles was moderate as on average studies reported on 66% of Consolidated Health Economic Evaluation Reporting Standards items.ConclusionsHEEs of AI in healthcare are limited and often focus on costs rather than health impact. Surprisingly, model-based long-term evaluations are just as uncommon as model-based short-term evaluations. Consequently, insight into the actual benefits offered by AI is lagging behind current technological developments. 相似文献
10.
目的 系统评价益气活血法联合西药治疗特发性肺纤维化(idiopathic pulmonary fibrosis,IPF)的疗效及安全性。方法 系统检索中国知网、维普网、万方数据库、EMbase、PubMed、Cochrane Library图书馆等数据库,检索时限从数据库建库至2021年1月,纳入益气活血法联合西药治疗特发性肺纤维化的随机对照试验(randomized controlled trial,RCT),由2名研究人员独立筛选并交叉核对纳入结果,提取有效数据后,应用RevMan 5.3软件进行Meta分析。结果 纳入16项随机对照试验共计1160例IPF患者。分析结果显示益气活血法联合西药组可提高临床总有效率(OR= 3.71,95% CI [2.68,5.14],P<0.00001);改善患者肺功能:用力肺活量(MD=0.31,95% CI [0.23,0.38],P<0.00001)(MD=3.59,95% CI [1.51,5.66],P=0.0007),一氧化碳弥散量(MD=2.54,95% CI [1.83,3.25],P<0.00001);提高生活质量,降低圣乔治评分:呼吸困难(MD=-12.70,95% CI [-21.07,-4.32],P=0.003),活动能力(MD=-8.38,95% CI [-13.66,-3.10],P=0.002),疾病影响(MD=-13.87,95% CI [-22.53,-5.22],P=0.002);并可降低患者中医症状积分:喘息(MD=-0.66,95% CI [-0.84,-0.49],P<0.00001),咳嗽(MD=-0.71,95% CI [-1.04,-0.37],P<0.0001);有效提高动脉血氧分压(MD=5.92,95% CI [4.61,7.22],P<0.00001);且不增加不良事件发生率(OR=0.55,95% CI [0.27,1.14],P=0.11)。结论 益气活血法联合西药治疗IPF可提高临床治疗有效率,改善患者生活质量,且不增加临床不良事件(便秘、嗜睡、口干、恶心呕吐、皮肤瘙痒、腹泻等)发生率。但本研究纳入文献质量参差不齐,仍需更多大样本、高质量、多中心的RCT试验验证结论。 相似文献